景峰医药(000908) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥173,311,877, a decrease of 17.40% compared to ¥209,812,385.67 in the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was a loss of ¥22,820,602.03, representing a decline of 25.43% from a loss of ¥18,294,564.77 in the previous year[5]. - The net loss for the period was reported at a staggering 4284.27% decline, attributed to decreased operating revenue and a smaller loss in the previous year[11]. - The net profit for Q3 2023 was -14,187,699.90 CNY, compared to -323,604.86 CNY in Q3 2022, indicating a significant decline in profitability[24]. - The total profit for the period was -6,980,284.62 CNY, down from 11,116,038.62 CNY in the same period last year[24]. - The total comprehensive income for the period was -13,816,947.22 CNY, compared to -145,074.19 CNY in Q3 2022[24]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 65.17%, amounting to ¥39,225,187.04 compared to ¥112,634,711.54 in the same period last year[5]. - Operating cash flow for the period was 39,225,187.04 CNY, a decrease of 65.2% from 112,634,711.54 CNY in the previous year[25]. - Cash inflow from operating activities totaled 640,735,354.30 CNY, down 13.1% from 737,223,267.34 CNY year-over-year[25]. - Cash outflow from operating activities was 601,510,167.26 CNY, compared to 624,588,555.80 CNY in the previous year[25]. - The net cash flow from investing activities was -11,979,355.30 CNY, a decline from 114,637,168.85 CNY in the same period last year[26]. - The net cash flow from financing activities was -33,993,574.49 CNY, compared to -213,339,100.02 CNY in Q3 2022, showing an improvement in cash management[26]. - The company's cash and cash equivalents decreased to ¥174,649,910.57 from ¥181,392,252.12, a decline of about 3.9%[20]. - The cash and cash equivalents at the end of the period were 174,649,910.57 CNY, down from 182,874,453.24 CNY at the end of the previous year[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,435,587,648.86, reflecting a decrease of 1.34% from ¥1,468,474,402.63 at the end of the previous year[5]. - As of September 30, 2023, total assets amounted to ¥1,435,587,648.86, a decrease from ¥1,455,112,046.92 at the beginning of the year[21]. - Total liabilities decreased to ¥1,247,938,491.19 from ¥1,253,645,942.02, indicating a slight reduction in financial obligations[21]. - The total equity attributable to shareholders decreased to ¥129,343,605.50 from ¥164,620,373.78, a decline of about 21.4%[22]. - The company reported a decrease in accounts payable to ¥112,847,315.32 from ¥138,543,285.29, reflecting a reduction of approximately 18.6%[21]. - Inventory levels decreased significantly to ¥81,168,058.94 from ¥120,368,198.90, indicating a reduction of approximately 32.5%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 73,253[12]. - The largest shareholder, Ye Xiangwu, holds 13.74% of shares, totaling 120,847,486 shares, with 90,635,614 shares under pledge or freeze[12]. - China Great Wall Asset Management Co., Ltd. holds 12.92% of shares, totaling 113,680,665 shares[12]. Regulatory and Governance - The company received an administrative regulatory measure from the China Securities Regulatory Commission, emphasizing the need for rectification in financial accounting and internal controls[17]. - The company is committed to enhancing its internal control system and governance level following the regulatory scrutiny[18]. - The company aims to strengthen compliance with laws and regulations to protect the rights of all shareholders[18]. - The company will continue to monitor the progress of legal disputes and ensure timely information disclosure[16]. Research and Development - The company capitalized 41.63% more in development expenditures this period, indicating increased investment in R&D[10]. - Research and development expenses were ¥14,067,503.36, down from ¥19,402,587.39, representing a decrease of approximately 27.5%[23]. Disputes and Investments - The company has ongoing disputes with Zhouyu Energy regarding the transfer of 43,988,718 shares, with a total transfer price of 219,943,590 RMB at 5 RMB per share[13]. - The company is actively seeking third-party investors to resolve disputes with Zhouyu Energy and improve cash flow[14].